Valuation: Arcutis Biotherapeutics, Inc.

Market Cap 3.18B 2.75B 2.57B 2.36B 4.43B 303B 4.5B 30.13B 11.82B 152B 11.94B 11.68B 501B P/E 2026 *
59.9x
P/E 2027 * 21.4x
Enterprise Value 2.89B 2.5B 2.33B 2.14B 4.03B 275B 4.09B 27.39B 10.75B 138B 10.85B 10.62B 456B EV / Sales 2026 *
5.38x
EV / Sales 2027 * 3.74x
Free-Float
97.73%
Yield 2026 *
-
Yield 2027 * -
1 day-4.31%
1 week-5.85%
Current month-5.85%
1 month-8.60%
3 months+22.41%
6 months-7.43%
Current year-12.91%
1 week 25.26
Extreme 25.265
29.24
1 month 25.26
Extreme 25.265
29.84
Current year 19.3
Extreme 19.295
30.75
1 year 14.03
Extreme 14.03
31.77
3 years 1.76
Extreme 1.76
31.77
5 years 1.76
Extreme 1.76
31.77
10 years 1.76
Extreme 1.76
40.88
Manager TitleAgeSince
Chief Executive Officer 58 01/04/2017
Corporate Officer/Principal 71 03/12/2025
Director of Finance/CFO - 15/05/2025
Director TitleAgeSince
Chairman 55 01/12/2019
Director/Board Member 58 01/01/2016
Director/Board Member 74 01/08/2020
Date Insider Type Main position Quantity % Market Cap.
8/3/26 A Sell

Chief Technology Officer

-955 0.0008%
8/3/26 A Sell

General Counsel

-1,230 0.0010%
8/3/26 A Sell

Chief Executive Officer

-4,375 0.0035%
Change 5-day change 1-year change 3-year change Capi.($)
-4.31%-5.85%+79.11%+163.99% 3.31B
+1.59%+2.85%+40.11%+1.24% 77.1B
-0.84%+0.09%+20.92%+179.15% 49.43B
+2.77%+4.78%-1.65%+27.62% 49.27B
-0.13%+7.42%-50.22%-49.58% 44.59B
+0.80%+2.46%+62.77%-23.33% 30.48B
+1.84%+0.87%+54.17%+85.73% 24B
+9.86%+7.94%+122.36%-41.53% 21.5B
+4.29%+9.40%+3.77%+226.51% 20.18B
+1.66%-3.70%+65.40%+123.91% 16.29B
Average +1.75%+1.87%+39.68%+69.37% 33.61B
Weighted average by Cap. +1.76%+3.15%+26.93%+46.67%

Financials

2026 *2027 *
Net sales 537M 465M 434M 398M 749M 51.13B 761M 5.09B 2B 25.63B 2.02B 1.97B 84.72B 680M 588M 549M 504M 948M 64.71B 963M 6.44B 2.53B 32.43B 2.55B 2.5B 107B
Net income 56.82M 49.15M 45.9M 42.11M 79.2M 5.41B 80.46M 539M 211M 2.71B 213M 209M 8.96B 169M 146M 136M 125M 235M 16.07B 239M 1.6B 628M 8.05B 634M 620M 26.63B
Net Debt -288M -249M -233M -214M -402M -27.45B -408M -2.73B -1.07B -13.76B -1.08B -1.06B -45.48B -638M -552M -515M -473M -889M -60.7B -903M -6.04B -2.37B -30.42B -2.39B -2.34B -101B
Logo Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. The Company develops therapies against biologically validated targets and produces a pipeline for a range of inflammatory dermatological conditions. Its portfolio consists of topical and systemic treatments to treat immune-mediated dermatological diseases and conditions. Its product portfolio includes ZORYVE Roflumilast Cream, ZORYVE Roflumilast Foam, and ARQ-234. The ZORYVE Roflumilast Cream is used for the treatment of seborrheic dermatitis in individuals aged 9 years and older. The ZORYVE Roflumilast Foam for the topical treatment of mild to moderate atopic dermatitis in adults and pediatric patients 6 years of age and older. The ARQ-234 is a fusion protein that is a checkpoint agonist of the CD200 Receptor (CD200R). CD200R is an immune-regulatory receptor which is an immunological checkpoint with a role in the maintenance of immune tolerance.
Employees
354
Date Price Change Volume
07/08/26 $25.29 -4.31% 2,448,156
06/08/26 $26.43 -2.47% 3,264,375
05/08/26 $27.10 +4.11% 2,448,788
04/08/26 $26.03 +0.35% 1,939,087
03/08/26 $25.94 -3.43% 1,570,530
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
25.29USD
Average target price
36.88USD
Spread / Average Target
+45.81%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ARQT Stock